Terra Alpha Investments LLC Acquires 2,277 Shares of IQVIA Holdings Inc. $IQV

Terra Alpha Investments LLC grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 23.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,893 shares of the medical research company’s stock after acquiring an additional 2,277 shares during the period. IQVIA accounts for about 2.3% of Terra Alpha Investments LLC’s investment portfolio, making the stock its 17th biggest position. Terra Alpha Investments LLC’s holdings in IQVIA were worth $2,259,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Versant Capital Management Inc lifted its holdings in IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after buying an additional 53 shares in the last quarter. Private Trust Co. NA raised its position in shares of IQVIA by 12.5% during the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after acquiring an additional 67 shares during the last quarter. CVA Family Office LLC lifted its stake in shares of IQVIA by 11.6% during the third quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 68 shares during the period. E Fund Management Co. Ltd. boosted its holdings in IQVIA by 3.7% in the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 74 shares during the last quarter. Finally, UMB Bank n.a. increased its position in IQVIA by 11.0% in the third quarter. UMB Bank n.a. now owns 749 shares of the medical research company’s stock worth $142,000 after purchasing an additional 74 shares during the period. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IQV. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. UBS Group raised their price objective on shares of IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Barclays set a $230.00 target price on shares of IQVIA in a research report on Monday, December 15th. Morgan Stanley raised their price target on IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Finally, Robert W. Baird set a $258.00 price objective on IQVIA and gave the company an “outperform” rating in a report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $251.06.

IQVIA Stock Down 2.4%

NYSE:IQV opened at $229.93 on Friday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock has a 50-day moving average price of $230.94 and a two-hundred day moving average price of $208.54. The stock has a market cap of $39.16 billion, a price-to-earnings ratio of 31.54, a PEG ratio of 2.39 and a beta of 1.36. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.